Search Results - "Quiroga García, Vanesa"

Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report by Quiroga García, Vanesa, Cirauqui Cirauqui, Beatriz, Tobey Robaina, Lyan, López Sisamon, David, Hardy-Werbin, Max, Blanca, Ana Belén, Margelí Vila, Mireia

“…Cancer patients with severe renal dysfunction represent a challenge for the physician. This is the first case report on the use of denosumab in a dialysis…”
Get full text

Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients by Quiroga-García, Vanesa, Cirauqui-Cirauqui, Beatriz, Bugés-Sánchez, Cristina, Luna-Tomás, Miguel Ángel, Castellà-Fernández, Eva María, Mariscal-Martínez, Antonio, Margelí-Vila, Mireia

“…Background: Treatment with aromatase inhibitors (AIs) followed by surgery is often recommended for women with locoregional hormone-sensitive breast cancer…”
Get full text

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck by Cirauqui, Beatriz Cirauqui, Peguera, Adrià Bernat, Pi-Sunyer, Ariadna Quer, Ferrando-Díez, Angelica, Serrano, Jose Luis Ramírez, Viñolas, Marta Domenech, García, Iris Teruel, García, Vanesa Quiroga, Oukadour, Imane Chaib, Valencia, Andrea González, Vergara, Pilar Hernández, de Aguirre Egaña, Itziar, Herrero, Cristina Queralt, Carbonell, Oscar Mesía, Paradís, Assumpció López, Esteve, Anna, Vila, Mireia Margelí, Rosell, Rafael, Martínez-Cardús, Anna, Mesía, Ricard

“…Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive disease with poor prognosis. It is known that the activation of STAT3 signaling pathways…”
Get full text

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report by Cirauqui, Beatriz Cirauqui, García, Vanesa Quiroga, Rubio, Clara Lezcano, Miguel, Maria Iciar Pascual, Riera, Laia Capdevila, Aranda, Nuria Pardo, Martín, Sara Vizcaya, Martínez, Antonio Mariscal, Caruncho, Clara Rodríguez, Vila, Mireia Margelí

“…Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including…”
Get full text

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients by Gligorov, J, Ataseven, B, Verrill, M, De Laurentiis, M, Jung, K.H, Azim, H.A, Al-Sakaff, N, Lauer, S, Shing, M, Pivot, X

“…Abstract Aim To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin® SC, H SC), delivered from an H SC Vial via hand-held…”
Get full text

Clinical algorithm to predict who may benefit from CDK4/6 inhibitors in patients (p) with estrogen receptor positive and HER-2 negative (ER+/Her2-) metastatic breast cancer (MBC) by Felip-Falgàs, Eudald, Teruel, Iris, García Mosquera, Juan José, Erasun, Carlos, Quiroga Garcia, Vanesa, Angelats, Laura, España, Sofia, Cucurull, Marc, Cirauqui, Beatriz, Vila, Mireia Margeli

“…Abstract only…”
Get full text

Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort by Palazón-Carrión, Natalia, Jiménez-Cortegana, Carlos, Holgado, Esther, Jurado, Josefina Cruz, Alonso Romero, Jose Luis, Sánchez Leon, María Luisa, Sanchez Margalet, Victor, Nogales, Esteban, Moreno Anton, Fernando, Quiroga Garcia, Vanesa, Andres, Raquel, Santisteban, Marta, Cortes, Javier, Rodríguez-Rodríguez, Luz Milva, Soto Gutierrez, Asuncion, Cortes, Mana Gion, Nieto Garcia, A., Chiesa, Massimo, Bezares, Susana, De la Cruz-Merino, Luis

“…Abstract only 2543 Background: High levels of myeloid-derived suppressor cells (MDSCs) seem a negative prognostic factor in advanced breast cancer (ABC)…”
Get full text

Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA) by Soria, Jean-Charles, Strickler, John H., Govindan, Ramaswamy, Chai, Seungjean, Chan, Nancy, Quiroga-Garcia, Vanesa, Bahleda, Rastislav, Hierro, Cinta, Zhong, Bob, Gonzalez, Martha, Santiago-Walker, Ademi E., Parekh, Trilok V., Luo, Feng Roger, Sullivan-Chang, Loretta, Xie, Hong, Tabernero, Josep

“…Abstract only 4074 Background: Erdafitinib (JNJ-42756493) is a potent, oral pan-FGFR tyrosine kinase inhibitor that demonstrated encouraging preliminary…”
Get full text

A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA 2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study) by De La Haba, Juan, Guerrero-Zotano, Angel, Perez-Fidalgo, Jose Alejandro, Gonzalez Santiago, Santiago, Muñoz, Montserrat, Andres, Raquel, Cruz Zambrano, Cristina, Moran Salama, Sebastian, Lopez-Tarruella, Sara, Quiroga Garcia, Vanesa, Servitja, Sonia, Mele, Mireia, Alonso Soler, Sonia, Adamo, Barbara, Escudero, Maria Jose, Martin, Nuria, Bezares, Susana, Caballero, Rosalia, Esteller, Manel, Rojo, Federico

“…Abstract only…”
Get full text